Acetato de enfuvirtida (T-20)
Alias:Fuzeon
Secuencia:CH3CO-Tyr-Thr-Ser-Leu-Ile-His-Ser-Leu-Ile-Glu-Glu-Ser-Gln-Asn-Gln-Gln-Glu-Lys-Asn-Glu-Gln-Glu-Leu-Leu- Glu-Leu-Asp-Lys-Trp-Ala-Ser-Leu-Trp-Asn-Trp-Phe-NH2
No CAS. : 159519-65-0
Fórmula molecular : C204H301N51O64
Peso molecular : 4492
Pureza (HPLC) : 98.0%min.
Apariencia : Sólido amorfo blanco a blanquecino
impureza única (HPLC) : 0.5%máximo
Composición de aminoácidos : ±10% del teórico
Contenido de péptidos (NORTE%) : ≥80,0%
Contenido de agua (karl fischer) : ≤8,0%
Contenido de trifluoroacetato(HPIC) : ≤12,0%
EM (ESI) : Coherente
Balance de masa : 95.0~105,0%
Calificación : Grado farmacéutico
Almacenamiento: Cerrado, abajo 2 ~ 8 ℃ preservación
Uso : Opción de tratamiento para pacientes que padecen VIH/SIDA.
Enfuvirtide is an antiretroviral drug used in combination therapy for the treatment of HIV-1/AIDS. It binds to the first heptad-repeat (HR1) in the gp41 subunit of the viral envelope glycoprotein and prevents the conformational changes required for the fusion of viral and cellular membranes. It works by disrupting the HIV-1 molecular machinery at the final stage of fusion with the target cell, preventing uninfected cells from becoming infected.
Enfuvirtide (POSADA) is an HIV fusion inhibitor, the first of a novel class of antiretroviral drugs used in combination therapy for the treatment of HIV-1 infection. It is marketed under the trade name Fuzeon (Roche).
